Foley Hoag advised Lantheus Holdings, Inc. (NASDAQ: LNTH), a leading radiopharmaceutical-focused company, in its recently announced exclusive licensing agreement with GE HealthCare (NASDAQ: GEHC) to develop, manufacture, and commercialize Lantheus' piflufolastat F18 (marketed as PYLARIFY® in the U.S.) in Japan for prostate cancer diagnostics and companion diagnostic use.
Under the terms of the agreement, GE HealthCare will pay Lantheus an upfront license fee, development milestones and tiered royalties based on product sales in Japan. The companies will also establish a joint steering committee to oversee development and commercialization activities.
Foley Hoag attorneys Sarah Cooleybeck, Jennifer Macarchuk, Ivanna Bihun, and Julia Dash advised Lantheus on the deal, with support from Earl Mellott, Nicole Kinsley, Alison Bauer, and Alexandra Levay.